ES2722723T3 - Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular - Google Patents

Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular Download PDF

Info

Publication number
ES2722723T3
ES2722723T3 ES11843788T ES11843788T ES2722723T3 ES 2722723 T3 ES2722723 T3 ES 2722723T3 ES 11843788 T ES11843788 T ES 11843788T ES 11843788 T ES11843788 T ES 11843788T ES 2722723 T3 ES2722723 T3 ES 2722723T3
Authority
ES
Spain
Prior art keywords
inflammation
vascular proliferation
methods
diseases associated
eye disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11843788T
Other languages
English (en)
Inventor
Darren James Kelly
David Stapleton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCCURX Pty Ltd
Original Assignee
OCCURX Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905197A external-priority patent/AU2010905197A0/en
Application filed by OCCURX Pty Ltd filed Critical OCCURX Pty Ltd
Application granted granted Critical
Publication of ES2722723T3 publication Critical patent/ES2722723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula 4 **(Ver fórmula)** para ser usado en el tratamiento de una enfermedad ocular asociada con inflamación y/o proliferación vascular en un sujeto; en que la enfermedad ocular se selecciona entre el grupo que comprende retinopatía diabética, edema corneal, uveítis anterior y posterior, pterigión, enfermedades corneales, ojo seco, conjuntivitis, exudación inducida por alergia y láser, degeneración macular no relacionada con la edad, edema macular, degeneración macular relacionada con la edad y enfermedad ocular de von Hippel-Lindau; en la que p es un número entero entre 1 y 10; y R se selecciona entre el grupo que consiste en H y alquilo de C1 a C10; o una sal farmacéuticamente aceptable del mismo.
ES11843788T 2010-11-24 2011-11-10 Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular Active ES2722723T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010905197A AU2010905197A0 (en) 2010-11-24 Methods of treating eye diseases associated with inflammation and vascular proliferation
PCT/AU2011/001455 WO2012068612A1 (en) 2010-11-24 2011-11-10 Methods of treating eye diseases associated with inflammation and vascular proliferation

Publications (1)

Publication Number Publication Date
ES2722723T3 true ES2722723T3 (es) 2019-08-16

Family

ID=46145280

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18207689T Active ES2829620T3 (es) 2010-11-24 2011-11-10 Procedimientos de tratamiento de enfermedades oculares asociadas con inflamación y proliferación vascular
ES11843788T Active ES2722723T3 (es) 2010-11-24 2011-11-10 Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18207689T Active ES2829620T3 (es) 2010-11-24 2011-11-10 Procedimientos de tratamiento de enfermedades oculares asociadas con inflamación y proliferación vascular

Country Status (21)

Country Link
US (5) US9839640B2 (es)
EP (2) EP2642989B1 (es)
JP (1) JP5942131B2 (es)
KR (1) KR101899613B1 (es)
CN (1) CN103228275B (es)
AU (1) AU2011334592C1 (es)
CA (1) CA2815390C (es)
DK (2) DK3485883T3 (es)
ES (2) ES2829620T3 (es)
HR (1) HRP20190561T1 (es)
HU (1) HUE042676T2 (es)
MX (1) MX352517B (es)
NZ (1) NZ609144A (es)
PL (1) PL2642989T3 (es)
PT (1) PT2642989T (es)
RS (1) RS58603B1 (es)
SG (1) SG189326A1 (es)
SI (1) SI2642989T1 (es)
TR (1) TR201904760T4 (es)
WO (1) WO2012068612A1 (es)
ZA (1) ZA201302638B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201904760T4 (tr) 2010-11-24 2019-04-22 Occurx Pty Ltd İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler.
CA3052036A1 (en) 2017-02-03 2018-08-09 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
CN110357789B (zh) * 2018-04-11 2022-09-30 华东理工大学 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
US20230270703A1 (en) * 2020-06-05 2023-08-31 Occurx Pty Ltd Compounds and methods for the treatment of eye disorders
EP4308541A1 (en) * 2021-03-17 2024-01-24 OccuRx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09176003A (ja) * 1995-12-28 1997-07-08 Tsumura & Co 角膜治療剤
KR19990082523A (ko) * 1996-02-15 1999-11-25 간자와 무츠와 혈관생성 억제제
JPH09278653A (ja) 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
JPH10259129A (ja) 1997-01-16 1998-09-29 Kissei Pharmaceut Co Ltd 血管新生阻害剤
AU739271B2 (en) 1997-02-14 2001-10-11 Kissei Pharmaceutical Co. Ltd. Agents inhibiting progress of pterygium and postoperative recurrence of the same
JPH10330254A (ja) * 1997-04-01 1998-12-15 Kissei Pharmaceut Co Ltd 翼状片の進行および術後の再発抑制剤
US20070254055A1 (en) * 2003-11-21 2007-11-01 Trustees Of Tufts College Therapeutic Avenanthramide Compounds
JP4966019B2 (ja) 2005-01-06 2012-07-04 キッセイ薬品工業株式会社 慢性移植片対宿主症におけるドライアイの予防および治療剤
SI2799427T1 (sl) * 2006-07-05 2018-12-31 Fibrotech Therapeutics Pty Ltd Terapevtske spojine
WO2008131481A1 (en) * 2007-04-26 2008-11-06 Fibrotech Therapeutics Pty Ltd Treatment of mesangioproliferative diseases
BRPI0814409A2 (pt) * 2007-07-06 2014-10-14 Nuon Therapeutics Inc Tratamento de dor neuropática
KR101593708B1 (ko) 2007-12-21 2016-02-12 피브로테크 세라퓨틱 피티와이 엘티디 항섬유증 제제의 할로겐화 유사체
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
WO2010144959A1 (en) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
TR201904760T4 (tr) 2010-11-24 2019-04-22 Occurx Pty Ltd İnflamasyon ve vasküler proliferasyon ile ilişkili göz hastalıklarının tedavi edilmesine yönelik yöntemler.

Also Published As

Publication number Publication date
EP2642989A1 (en) 2013-10-02
AU2011334592C1 (en) 2015-04-02
JP2014502267A (ja) 2014-01-30
WO2012068612A1 (en) 2012-05-31
US10786510B2 (en) 2020-09-29
HUE042676T2 (hu) 2019-07-29
RS58603B1 (sr) 2019-05-31
PT2642989T (pt) 2019-04-23
MX352517B (es) 2017-04-06
US20210244741A1 (en) 2021-08-12
SG189326A1 (en) 2013-05-31
MX2013005561A (es) 2014-11-10
US20180117050A1 (en) 2018-05-03
PL2642989T3 (pl) 2019-07-31
JP5942131B2 (ja) 2016-06-29
US20180117051A1 (en) 2018-05-03
EP3485883B1 (en) 2020-08-26
EP2642989A4 (en) 2014-09-24
DK2642989T3 (en) 2019-04-15
NZ609144A (en) 2014-08-29
AU2011334592B2 (en) 2014-10-23
SI2642989T1 (sl) 2019-07-31
US9839640B2 (en) 2017-12-12
EP3485883A1 (en) 2019-05-22
US11583535B2 (en) 2023-02-21
CA2815390A1 (en) 2012-05-31
CN103228275A (zh) 2013-07-31
EP2642989B1 (en) 2019-01-02
US10695353B2 (en) 2020-06-30
AU2011334592A1 (en) 2013-05-02
CN103228275B (zh) 2016-08-10
TR201904760T4 (tr) 2019-04-22
CA2815390C (en) 2021-07-13
DK3485883T3 (da) 2020-10-12
US20130310386A1 (en) 2013-11-21
US20180117049A1 (en) 2018-05-03
ES2829620T3 (es) 2021-06-01
KR20140012032A (ko) 2014-01-29
KR101899613B1 (ko) 2018-09-17
HRP20190561T1 (hr) 2019-06-14
ZA201302638B (en) 2023-07-26

Similar Documents

Publication Publication Date Title
JOP20170147B1 (ar) تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
BR112014008759A2 (pt) tratamento de doença ocular
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
ES2722723T3 (es) Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
AR098693A1 (es) Método para producir células del epitelio pigmentario retiniano (rpe)
CU24091B1 (es) Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden
MX360683B (es) Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201490012A1 (ru) Опсин-связывающие лиганды, композиции и способы их использования
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EA201591180A1 (ru) Составы ингибитора lfa-1